Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...

SAN FRANCISCO -- Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when ...

The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Alerts delivered via the electronic health record temporarily reduces unnecessary screening and treatment but does not create ...

The 63-year-old musician revealed his stage 4 prostate cancer diagnosis in November 2022, saying his cancer was “asymptomatic ...

Having raised more than $1 million toward cancer research over the past nine years, the tournament is on the road to raising ...

The Elekta Unity MR-LINAC system combines MRI imaging with radiation therapy to target cancerous cells with pinpoint ...

A ground-breaking treatment for cancer described by doctors as being like a ‘heat seeking missile’ has boosted survival rates and quality of life for patients with fewer side effects.